Welcome to Trends-in-Medicine, offering independent, cutting-edge articles and information on drugs and devices in development. Our subscribers have access to news and analysis on the latest data, regulatory issues, and trends of interest to the healthcare community.

Quick Takes for January 11, 2026

ASCO-GI

Data presented at ASCO-GI is likely to change how colorectal cancer (CRC) is treated. One study showed that GLP-1 receptor agonists are better than aspirin for primary prevention of CRC, and an update on the BREAKWATER trial showed that Pfizer's Braftovi (encorafenib) + cetuximab + FOLFIRI (for patients who can't or won't take FOLFOX) is an effective option for BRAFV600E-mutant metastatic CRC

TCT Preview

Here is a quick look at some of the things being presented at TCT 2025 in San Francisco that stand out

EURETINA bulletin

At the 2025 EURETINA Congress in Paris, two presentations provided promising new data on Oculis’ OCS-01 (a high concentration dexamethasone topical eye drop) for diabetic macular edema (DME). A third study reported on Oculis’ privosegtor (OCS-05), an intravenous SGK2 agonist and neuroprotective agent, in acute optic neuritis.

MAHA and Drug Pricing

The Food and Drug Law Institute (FDLI) hosted a webinar on what the Make America Healthy Again (MAHA) agenda means for drug pricing. Here is what the 4 lawyers who participated predicted.

Obesity Xtalk

Here we report on an Xtalks webinar by Premier Research on “Innovating Obesity Treatments for Real-World Impact.”

FDLI Annual Conference report

The hot topics at the meeting this year were: Changes at FDA – from personnel to focus, priorities, accelerated review, clinical trials, and more; the impact of President Trump’s executive orders; artificial intelligence, drug compounding, and controlled substances.